chartexchange

Sellas To Present SLS009 Data At American Society of Hematology – Initial Results Of Therapy In Newly Diagnosed AML Patients Expected In Q4

Stocktwits | Nov 4, 2026 11:40 AM EST

The Phase 2 study evaluated SLS009 alongside Azacitidine and Venetoclax in 62 patients with AML.

Read original article